Hirsch Alexander, Verouden Niels J W, Koch Karel T, Baan Jan, Henriques José P S, Piek Jan J, Rohling Wim J, van der Schaaf Rene J, Tijssen Jan G P, Vis Marije M, de Winter Robbert J
Department of Cardiology, University of Amsterdam Academic Medical Center, Amsterdam, The Netherlands.
Am J Cardiol. 2009 Aug 1;104(3):333-7. doi: 10.1016/j.amjcard.2009.03.052. Epub 2009 Jun 6.
Data remain limited regarding the comparative long-term mortality across the spectrum of patients with different indications for percutaneous coronary intervention (PCI). We evaluated early and late mortality in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary PCI compared with early and late mortality in patients undergoing PCI for unstable angina (UA) or non-STEMI (NSTEMI) and stable angina. A total of 10,549 consecutive patients undergoing PCI from 1997 to 2005 at a single institution were followed up prospectively (median 3.2 years, interquartile range 1.5 to 5.6) to assess all-cause mortality. The indication for PCI was STEMI in 28%, UA/NSTEMI in 32%, and stable angina in 40%. The mortality rate at 6 years was 18.9% in patients with STEMI, 16.2% in patients with UA/NSTEMI, and 11.7% in those with stable angina. During the initial 6 months, patients with STEMI had an increased risk of death compared with patients with UA/NSTEMI (relative risk [RR] 3.09, 95% confidence interval [CI] 2.46 to 3.89) and stable angina (RR 5.82, 95% CI 4.45 to 7.62). However, between 6 months and 6 years, mortality accrued at an almost similar rate among patients with STEMI and those with stable angina (RR 1.06, 95% CI 0.86 to 1.32) and mortality was greatest in patients with UA/NSTEMI (UA/NSTEMI vs stable angina: RR 1.33, 95% CI 1.11 to 1.58; STEMI vs UA/NSTEMI: RR 0.80, 95% CI 0.65 to 0.99). In conclusion, we have demonstrated that the inferior survival rates in patients with STEMI after primary PCI are mainly attributed to greater mortality in the first months after the event. These observations highlight that new adjunctive therapeutic strategies should aim at mortality reduction in the first months after primary PCI.
关于不同经皮冠状动脉介入治疗(PCI)适应证患者的长期死亡率比较,相关数据仍然有限。我们评估了接受直接PCI治疗的ST段抬高型心肌梗死(STEMI)患者的早期和晚期死亡率,并与因不稳定型心绞痛(UA)或非STEMI(NSTEMI)以及稳定型心绞痛接受PCI治疗的患者的早期和晚期死亡率进行了比较。1997年至2005年期间,在一家机构连续接受PCI治疗的10549例患者接受了前瞻性随访(中位时间3.2年,四分位间距1.5至5.6年),以评估全因死亡率。PCI的适应证为STEMI的患者占28%,UA/NSTEMI的患者占32%,稳定型心绞痛的患者占40%。STEMI患者6年时的死亡率为18.9%,UA/NSTEMI患者为16.2%,稳定型心绞痛患者为11.7%。在最初的6个月内,与UA/NSTEMI患者(相对风险[RR]3.09,95%置信区间[CI]2.46至3.89)和稳定型心绞痛患者(RR 5.82,95%CI 4.45至7.62)相比,STEMI患者的死亡风险增加。然而,在6个月至6年之间,STEMI患者和稳定型心绞痛患者的死亡率累积速率几乎相似(RR 1.06,95%CI 0.86至1.32),而UA/NSTEMI患者的死亡率最高(UA/NSTEMI与稳定型心绞痛相比:RR 1.33,95%CI 1.11至1.58;STEMI与UA/NSTEMI相比:RR 0.80,95%CI 0.65至0.99)。总之,我们已经证明,直接PCI后STEMI患者生存率较低主要归因于事件发生后头几个月的较高死亡率。这些观察结果突出表明,新的辅助治疗策略应旨在降低直接PCI后最初几个月的死亡率。